StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX – Free Report) in a report issued on Monday morning. The brokerage issued a sell rating on the stock.
Separately, Cantor Fitzgerald reissued an overweight rating and issued a $2.50 price target on shares of VolitionRx in a research note on Thursday, May 16th.
Get Our Latest Analysis on VolitionRx
VolitionRx Price Performance
VolitionRx (NYSE:VNRX – Get Free Report) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.27 million. As a group, sell-side analysts anticipate that VolitionRx will post -0.31 EPS for the current year.
Institutional Investors Weigh In On VolitionRx
An institutional investor recently bought a new position in VolitionRx stock. Silverberg Bernstein Capital Management LLC bought a new stake in shares of VolitionRx Limited (NYSE:VNRX – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned 0.19% of VolitionRx at the end of the most recent reporting period. 8.09% of the stock is currently owned by institutional investors.
VolitionRx Company Profile
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Further Reading
- Five stocks we like better than VolitionRx
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- This Cybersecurity Stock Gains Analysts’ Favor for Strong Growth
- How to Calculate Stock Profit
- Parabolic Rise of This Stock Shows No Signs of Slowing
- P/E Ratio Calculation: How to Assess Stocks
- Risk Tolerance vs. Risk Appetite: Key Differences
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.